证券代码：600267 证券简称：海正药业 公告编号：临 2025-05 号 浙江海正药业股份有限公司 2024 年年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例：每股派发现金红利 0.21 元（含税） 本次利润分配以实施权益分派股权登记日登记的总股本扣除浙江海正药 业股份有限公司（以下简称"公司"）回购专用证券账户股份数后的股本为基数， 具体日期将在权益分派实施公告中明确。在实施权益分派股权登记日期前，公司 总股本扣除公司回购专用证券账户中股份的基数发生变动的，拟维持每股分配金 额不变，相应调整分配总额，并将在相关公告中披露。 公司没有触及《上海证券交易所股票上市规则（2024 年 4 月修订）》（以 下简称"《股票上市规则》"）第 9.8.1 条第一款第（八）项规定的可能被实施其他 风险警示的情形。 （一）董事会会议的召开、审议和表决情况 公司拟向全体股东每 10 股派发现金 2.10 元（含税），公司通过回购专用账 户所持有本公司股份不参与本次利润分配。截至 2024 ...

Financial Performance - The company's operating revenue for 2024 was CNY 9,786,848,052.59, a decrease of 5.65% compared to CNY 10,373,071,956.92 in 2023[22]. - The net profit attributable to shareholders for 2024 was CNY 601,182,827.25, a significant recovery from a loss of CNY 93,171,306.60 in 2023[22]. - The net cash flow from operating activities increased by 40.72% to CNY 2,114,532,552.48 in 2024, compared to CNY 1,502,669,446.74 in 2023[22]. - Basic earnings per share for 2024 were CNY 0.52, a recovery from a loss of CNY 0.08 in 2023[23]. - The weighted average return on equity increased to 7.43% in 2024, up by 8.58 percentage points from -1.15% in 2023[23]. - The total assets decreased by 9.32% to CNY 15,972,478,068.00 at the end of 2024, down from CNY 17,613,281,702.72 at the end of 2023[22]. - The net profit after deducting non-recurring gains and losses for 2024 was CNY 422,556,636.62, compared to a loss of CNY 100,015,816.10 in 2023[22]. - The company reported a net profit of CNY 248,531,288.09 in the first quarter of 2024, with a steady increase in subsequent quarters[25]. - Non-recurring gains for 2024 totaled CNY 178,626,190.63, significantly higher than CNY 6,844,509.50 in 2023[28]. Dividend and Share Repurchase - The company plans to distribute a cash dividend of 2.10 RMB per 10 shares, totaling approximately 245.42 million RMB, which represents 56.87% of the net profit attributable to shareholders for the year[6]. - The total amount spent on share repurchase during the year was approximately 96.46 million RMB, contributing to a combined cash distribution and repurchase amount of approximately 341.88 million RMB[6]. - The company does not plan to issue new shares or convert capital reserves into share capital this year[6]. Corporate Governance - The company has maintained a robust corporate governance structure, ensuring compliance with relevant laws and regulations, and protecting shareholder rights[170]. - The board of directors consists of 7 members, including 3 independent directors, ensuring a fair and transparent selection process[171]. - The company actively engages with investors through various channels to ensure timely communication and protect investor interests[172]. - The company adheres to strict information disclosure obligations, enhancing transparency and preventing insider trading[172]. - The company held its first extraordinary general meeting of 2024 on February 21, where all proposed resolutions were approved[173]. - The annual general meeting for 2023 was held on May 20, 2024, and all resolutions, including the financial budget for 2024, were approved[175]. Research and Development - The company has invested 170 million yuan in a flexible production line project for synthetic biology, which is currently under implementation[39]. - The company submitted 12 domestic and international registration applications, including 1 innovative drug, and initiated 42 new R&D projects[40]. - The company applied for 62 patents during the reporting period, with 30 patents granted, further strengthening its technological barriers[41]. - The company has established a research and development network through strategic partnerships with various domestic and international research institutions and biotechnology companies[75]. - The company achieved a total R&D investment of 416 million RMB in the reporting period, with 358 million RMB classified as expense-based R&D investment, reflecting an increase compared to the previous year[124]. Market Expansion and Strategy - The company aims to improve product accessibility by expanding its presence in county hospitals and grassroots medical institutions, thereby serving more patients in the future[49]. - The company is actively involved in the production and supply of essential cancer treatment drugs, responding to national calls to restore the supply of critical medications[52]. - The company is committed to high standards in selecting agents and optimizing business layouts to enhance market penetration and compliance[53]. - The company is focusing on core research areas such as cardiovascular and metabolic diseases while expanding into emerging sectors like medical aesthetics and health[124]. - The company is accelerating its internationalization efforts, focusing on markets such as the US, Middle East, South America, Southeast Asia, and Russia[158]. Compliance and Risk Management - The company emphasizes strict adherence to legal and regulatory requirements, prohibiting any form of commercial bribery[115]. - The company is focusing on independent research and innovation, as well as the introduction of new products to adapt to market changes[112]. - The pharmaceutical industry is facing dual challenges of cost pressure and intensified market competition due to policies like centralized procurement and drug price governance[110]. - The company is highly dependent on raw materials such as food and chemical products, with price fluctuations significantly impacting production costs and profitability[167]. - Government policies aimed at reducing medical costs may lead to continued price reductions in the pharmaceutical market, potentially decreasing average profit margins in the industry[168]. Employee and Management Structure - The total number of employees in the parent company is 2,859, while the main subsidiaries employ 5,135, resulting in a total of 7,994 employees[199]. - The educational background of employees includes 461 with postgraduate degrees, 2,985 with bachelor's degrees, 4,105 with vocational diplomas, and 443 with high school or lower education[199]. - The company aims to establish a fair and motivating compensation system linked to economic performance and individual achievements[200]. - The compensation policy emphasizes a performance-based approach to incentivize employee productivity and engagement[200]. - The company appointed Jiang Ling as Senior Vice President and Chief Financial Officer on April 26, 2024[187]. Product Development and Innovation - The company launched 4 new veterinary drugs and received approval for 5 new veterinary drugs during the reporting period, with 9 products achieving sales over 10 million[35]. - The company is investing $50 million in R&D for new technologies aimed at enhancing product efficacy and safety[127]. - New product launches included a veterinary vaccine that targets multiple diseases, expected to capture a 10% market share within the first year[128]. - The company has successfully bid for several key drugs in centralized procurement, including Amlodipine Atorvastatin Calcium Tablets with a procurement volume of 4,429,090 units[120]. Financial Strategy and Investments - The company plans to conduct foreign exchange hedging business as part of its financial strategy[188]. - The company will utilize idle funds for wealth management products as part of its investment strategy[188]. - The company has approved a plan to repurchase and cancel part of the restricted stock incentive plan from 2021[194]. - The company has completed several major non-equity investments, including a 46,354.12 million RMB project for the expansion of injection production capacity[140].

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.5200 | -0.0800 | 750 | 0.4200 | | 每股净资产（元） | 6.96 | 6.43 | 8.24 | 6.39 | | 每股公积金(元) | 3.58 | 3.6 | -0.56 | 3.47 | | 每股未分配利润(元) | 2.12 | 1.64 | 29.27 | 1.93 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 97.87 | 103.73 | -5.65 | 120.37 | | 净利润(亿元) | 6.01 | -0.93 | 746.24 | 4.89 | | 净资产收益率(%) | 7.43 | -1.15 | 746.09 | 6.38 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 51690.89万股，累计占流通股比： 43.1 ...

近日，海正药业公告，获得国家药品监督管理局核发的依维莫司片《药品注册证书》。资料显示，依维 莫司片是一种靶向抗癌药物，主要用于治疗多种晚期癌症和肿瘤。据统计，依维莫司片2023年全球销售 额约为111367.82万美元，其中国内销售额约为861.37万美元；2024年1—9月全球销售额约为76087.49万 美元，其中国内销售额约为770.99万美元。 此外，海正药业积极贯彻市值管理政策，采取股份回购、投资参股及加强资本市场沟通等举措，维护股 东利益。2024年4月，公司按计划完成第三次股份回购，累计回购3017.63万股，占总股本比例2.50%； 12月，公司拟以5000万元参与增资研发型生物医药企业吉盛澳玛，聚焦研发创新，推进创新药战略落 地；同时通过公告、召开股东大会、组织机构投资者现场交流、回复e互动问题等方式，持续加强与资 本市场高频次沟通，及时传递公司价值信息。 除了聚焦业务发展，海正药业还以实际行动践行社会责任，彰显国企责任与使命。近日，公司为日喀则 市定日县提供百万抗流感药物援助，护航西藏震区群众平安健康过春节，并为台州市椒江区的对口帮扶 城市四川甘孜藏族自治州色达县提供价值84万元药品用于应 ...

Financial Performance Expectations - The company expects a net profit attributable to shareholders of between 570 million and 630 million yuan for the year 2024, marking a turnaround from a loss in the previous year[2] - The net profit after deducting non-recurring gains and losses is projected to be between 400 million and 460 million yuan for 2024[2] - In the same period last year, the company reported a net loss of 931.71 million yuan, indicating a significant improvement in performance[4] Factors Contributing to Profit - The company attributes the expected profit to marketing transformation, overcoming product price declines, and significant improvements in operational efficiency[5] - The company anticipates an increase in investment income of approximately 155 million yuan due to the redemption of convertible bonds, contributing to non-recurring gains[5] Earnings Forecast and Audit - The earnings forecast has been preliminarily discussed with the accounting firm, with no significant discrepancies noted[3] - The company has not identified any major uncertainties that could impact the earnings forecast[6] - The financial data provided is preliminary and subject to final audit in the official annual report[7]

1月7日，一场6.8级地震突袭西藏日喀则市定日县，这是该县有历史记录以来发生的最大地震。 证券时报e公司讯，记者获悉，1月15、16日，海正药业旗下子公司瀚晖制药的杭州富阳厂区和海正药业 外沙工厂发车奔赴日喀则，捐赠抗流感药物，这些药物包括新型广谱抗流感病毒药品法维拉韦，及美罗 培南、亚胺培南等药品，均为海正药业自主生产的药物，价值总额超100万元。 截至今日，该地区余震仍时有发生。 据悉，这些灾区急需的药品将由西藏自治区总工会，日喀则市工会转交给当地医疗机构，帮助医生更好 地应对流感传播风险。 同时，地震时值寒冷冬日，灾区密集的人员流动也令流感等呼吸道疾病更易高发。 ...

浙江海正药业股份有限公司会计师事务所选聘制度 浙江海正药业股份有限公司 会计师事务所选聘制度 第一章 总则 第一条 为进一步规范浙江海正药业股份有限公司（以下简称"公司"）选聘 （含续聘、改聘，下同）会计师事务所相关行为，切实维护股东利益，提高审计工作 和财务信息的质量，依据《中华人民共和国公司法》《中华人民共和国证券法》《国 有企业、上市公司选聘会计师事务所管理办法》《上海证券交易所股票上市规则》《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》及《浙江海正药业股份有 限公司章程》（以下简称《公司章程》）等有关规定，结合公司实际情况，制定本制 度。 第二条 本制度所称选聘会计师事务所，是指公司根据相关法律法规要求，聘 任会计师事务所对财务会计报告发表审计意见、出具审计报告的行为。公司选聘进行 财务报表审计业务、内部控制审计业务的会计师事务所，需遵照本制度的规定。选聘 其他专项审计业务的会计师事务所，公司管理层视重要性程度可参照本制度执行。 第三条 公司选聘会计师事务所应当经董事会审计委员会（以下简称"审计委 员会"）审议同意后，提交董事会审议，并由股东大会决定。公司不得在董事会、股 东大会审议前 ...

浙江海正药业股份有限公司 第九届董事会第三十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江海正药业股份有限公司（以下简称"公司"或"海正药业"）第九届董 事会第三十四次会议于 2024 年 12 月 27 日（周五）下午在台州椒江公司会议室 以现场加通讯方式召开，应参加会议董事 7 人，亲自参加会议董事 7 人，公司监 事及高管人员列席了会议。本次会议的召开程序符合《公司法》和《公司章程》 的规定，会议合法有效。本次会议由公司董事长肖卫红先生主持，经与会董事认 真讨论研究，会议审议并通过了如下决议： 一、关于投资参股南京吉盛澳玛生物医药有限公司的议案； 南京吉盛澳玛生物医药有限公司（以下简称"吉盛澳玛"）成立于 2021 年， 产品主要适应症包括过敏性鼻炎、过敏性皮炎、呼吸道感染、疫苗佐剂等，为支 持其自身创新药的研发，吉盛澳玛近期计划融资不超过 1 亿元。鉴于吉盛澳玛管 线产品应用疾病领域符合公司发展战略，为促进与吉盛澳玛合作及推进公司自身 创新药发展，同意公司以 5,000 万元自筹资金参与吉盛澳玛 ...

证券代码：600267 证券简称：海正药业 公告编号：临 2024-130 号 浙江海正药业股份有限公司 关于参与设立的投资基金变更有限合伙人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2021年11月16日，浙江海正药业股份有限公司（以下简称"公司"）第八届 董事会第三十五次会议审议通过了《关于参与投资台州椒江英飞海正创收投资合 伙企业（有限合伙）的议案》，同意公司及全资子公司浙江海正投资管理有限公 司与台州市英飞创收创业投资有限公司、英飞尼迪贰号（珠海）创业投资合伙企 业（有限合伙）、台州市资产管理有限公司、台州湾科创谷投资有限公司以自有 资金共同投资由英飞尼迪（珠海）创业投资管理有限公司牵头设立的台州椒江英 飞海正创收创业投资合伙企业（有限合伙）（以下简称"英飞海正投资"）。英 飞海正投资于2022年1月在中国证券投资基金业协会完成私募投资基金备案手续， 取得《私募投资基金备案证明》。具体内容详见公司于2021年11月17日、2022年 1月20日在《中国证券报》《上海证券报》《证券时报》和上海证券交易所网站 ...

浙江海正药业股份有限公司董事会战略与可持续发展委员会实施细则 浙江海正药业股份有限公司 董事会战略与可持续发展委员会实施细则 第一章 总则 第一条 为适应公司战略发展需要，增强公司核心竞争力，确定公司发展规划， 健全投资决策程序，加强决策科学性，提高重大投资决策的效益和决策的质量，完善 公司治理结构，发展并落实公司环境、社会及治理工作，根据《中华人民共和国公司 法》、《上市公司治理准则》、《公司章程》及其他有关规定，公司设立董事会战略与可 持续发展委员会，并制定本实施细则。 第二条 战略与可持续发展委员会是董事会下设的专门工作机构，主要负责对公 司的长期发展规划、重大投资决策以及 ESG（环境、社会及治理）事宜进行研究并提 出建议。 第二章 人员组成 第三条 战略与可持续发展委员会成员由五名董事组成，其中应至少包括一名独 立董事。 第四条 战略与可持续发展委员会委员由董事长、二分之一以上独立董事或者全 体董事的三分之一提名，并由董事会选举产生。战略与可持续发展委员会委员应熟悉 国家有关法律、法规和公司的经营管理；有较强的综合分析和判断能力，能判断涉及 公司发展战略、重大投资以及 ESG（环境、社会及治理）方面 ...